Management of Functional Pancreatic Neuroendocrine Neoplasms

Overview

Journal Curr Treat Options Oncol

Specialty Oncology

Date 2023 Apr 27

PMID 37103745

Authors

Ludovica Magi

Matteo Marasco

Maria Rinzivillo

Antongiulio Faggiano

Francesco Panzuto

Affiliations

Soon will be listed here.

Abstract

Functional pancreatic neuroendocrine neoplasms (pNENs) are rare and heterogeneous diseases in terms of both clinical and pathological aspects. These tumors secrete hormones or peptides, which may cause a wide variety of symptoms related to a clinical syndrome. The management of functional pNENs is still challenging for clinicians due to the need to control both tumor growth and specific symptoms. Surgery remains the cornerstone in the management of local disease because it can definitively cure the patient. However, when the disease is not resectable, a broad spectrum of therapeutic options, including locoregional therapy, somatostatin analogs (SSAs), targeted therapies, peptide-receptor radionuclide therapy (PRRT), and chemotherapy, are available. The present review summarizes the main key issues regarding the clinical management of these tumors, providing a specific highlight on their therapeutic approach.

Citing Articles

Initial Application of Fluorescence Imaging for Intraoperative Localization of Small Neuroendocrine Tumors in the Pancreas: Case Report and Review of the Literature.

Xi S, Zheng X, Wang X, Jiang B, Shen Z, Wang G J Gastrointest Cancer. 2024; 56(1):23.

PMID: 39562390 PMC: 11576835. DOI: 10.1007/s12029-024-01143-2.

All Neuroendocrine Tumors Seem to Look Alike but Some Look Alike More Than Others.

Santos A GE Port J Gastroenterol. 2024; 31(5):303-305.

PMID: 39360173 PMC: 11444703. DOI: 10.1159/000539161.

miRNA Expression Profiling in G1 and G2 Pancreatic Neuroendocrine Tumors.

Nyiro G, Szeredas B, Decmann A, Herold Z, Vekony B, Borka K Cancers (Basel). 2024; 16(14).

PMID: 39061169 PMC: 11275009. DOI: 10.3390/cancers16142528.

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian.

Cortiana V, Abbas R, Chorya H, Gambill J, Mahendru D, Park C Cancers (Basel). 2024; 16(13).

PMID: 39001391 PMC: 11240738. DOI: 10.3390/cancers16132329.

Surgical Management and Long-Term Evaluation of Pancreatic Neuroendocrine Tumors.

Ghabra S, Ramamoorthy B, Andrews S, Sadowski S Surg Clin North Am. 2024; 104(4):891-908.

PMID: 38944507 PMC: 11214659. DOI: 10.1016/j.suc.2024.02.019.

References

Thakker R, Newey P, Walls G, Bilezikian J, Dralle H, Ebeling P . Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9):2990-3011. DOI: 10.1210/jc.2012-1230. View

Cives M, Strosberg J . Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018; 68(6):471-487. DOI: 10.3322/caac.21493. View

Banerjee A, Shah S . Necrolytic Migratory Erythema Associated with a Glucagonoma. N Engl J Med. 2020; 383(6):e39. DOI: 10.1056/NEJMicm1915564. View

Crino S, Napoleon B, Facciorusso A, Lakhtakia S, Borbath I, Caillol F . Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma. Clin Gastroenterol Hepatol. 2023; 21(11):2834-2843.e2. DOI: 10.1016/j.cgh.2023.02.022. View

Magi L, Mazzuca F, Rinzivillo M, Arrivi G, Pilozzi E, Prosperi D . Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. J Clin Med. 2019; 8(6). PMC: 6616416. DOI: 10.3390/jcm8060910. View

Partelli S, Bartsch D, Capdevila J, Chen J, Knigge U, Niederle B . ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2017; 105(3):255-265. DOI: 10.1159/000464292. View

Lee L, Ito T, Jensen R . Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019; 19(12):1029-1050. PMC: 6923565. DOI: 10.1080/14737140.2019.1693893. View

Barat M, Cottereau A, Kedra A, Dermine S, Palmieri L, Coriat R . The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J Clin Med. 2020; 9(7). PMC: 7408651. DOI: 10.3390/jcm9072302. View

Peltola E, Hannula P, Huhtala H, Metso S, Sand J, Laukkarinen J . Long-term morbidity and mortality in patients diagnosed with an insulinoma. Eur J Endocrinol. 2021; 185(4):577-586. PMC: 8784472. DOI: 10.1530/EJE-21-0230. View

10.

Panzuto F, Magi L, Rinzivillo M . Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia. Expert Opin Drug Saf. 2021; 20(4):383-386. DOI: 10.1080/14740338.2021.1881478. View

11.

Feelders R, Newell-Price J, Pivonello R, Nieman L, Hofland L, Lacroix A . Advances in the medical treatment of Cushing's syndrome. Lancet Diabetes Endocrinol. 2018; 7(4):300-312. DOI: 10.1016/S2213-8587(18)30155-4. View

12.

Maggio I, Mollica V, Brighi N, Lamberti G, Manuzzi L, Ricci A . The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest. 2019; 43(2):139-148. DOI: 10.1007/s40618-019-01091-w. View

13.

Zandee W, Brabander T, Blazevic A, Kam B, Teunissen J, Feelders R . Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab. 2018; 104(4):1336-1344. DOI: 10.1210/jc.2018-01991. View

14.

Rossi R, Elvevi A, Citterio D, Coppa J, Invernizzi P, Mazzaferro V . Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World J Gastroenterol. 2021; 27(35):5890-5907. PMC: 8475006. DOI: 10.3748/wjg.v27.i35.5890. View

15.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

16.

Burns W, Edil B . Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol. 2011; 13(1):24-34. DOI: 10.1007/s11864-011-0172-2. View

17.

Siddappa P, Vege S . Vasoactive Intestinal Peptide-Secreting Tumors: A Review. Pancreas. 2019; 48(9):1119-1125. DOI: 10.1097/MPA.0000000000001402. View

18.

Falconi M, Eriksson B, Kaltsas G, Bartsch D, Capdevila J, Caplin M . ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016; 103(2):153-71. PMC: 4849884. DOI: 10.1159/000443171. View

19.

Norton J, Krampitz G, Poultsides G, Visser B, Fraker D, Alexander H . Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome. Ann Surg. 2018; 267(4):782-788. DOI: 10.1097/SLA.0000000000002122. View

20.

Panzuto F, Merola E, Pavel M, Rinke A, Kump P, Partelli S . Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist. 2017; 22(4):409-415. PMC: 5388376. DOI: 10.1634/theoncologist.2016-0351. View